摘要
目的:观察益气化痰方联合化疗对老年晚期非小细胞肺癌(non-small cell lung carcinoma,NSCLC)气阴两虚证患者的疗效。方法:回顾性分析2019年6月至2021年6月该院收治的74例老年晚期NSCLC气阴两虚证患者的临床资料,按照治疗方式不同将其分为对照组和观察组各37例。对照组采用GP化疗方案治疗,观察组在对照组基础上联合益气化痰方治疗。比较两组客观缓解率、治疗前后中医证候积分、T细胞亚群指标(CD3^(+)、CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+))水平、卡氏评分法(KPS)评分,以及不良反应发生率。结果:治疗后,观察组客观缓解率为78.38%(29/37),高于对照组的54.05%(20/37),差异有统计学意义(P<0.05);观察组中医证候积分低于对照组,差异有统计学意义(P<0.05);观察组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)水平和KPS评分均高于对照组,CD8^(+)水平低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:益气化痰方联合化疗可提高老年晚期NSCLC气阴两虚证患者客观缓解率、KPS评分,改善T细胞亚群指标水平,降低中医证候积分,效果优于单纯GP化疗方案治疗。
Objective: To observe effects of Yiqi Huatan decoction combined with chemotherapy in treatment of elderly patients with advanced non-small cell lung cancer(NSCLC) with of qi and yin deficiency syndrome. Methods: The clinical data of 74 elderly patients with advanced NSCLC with qi and yin deficiency syndrome admitted to the hospital from June 2019 to June 2021 were retrospectively analyzed.According to different treatment methods, they were divided into control group and observation group, 37 cases in each group. The control group was treated with GP chemotherapy, while the observation group was treated with Yiqi Huatan decoction on the basis of that of the control group.The clinical efficacy, the TCM syndrome scores before and after the treatment, the T cell subset levels(CD3^(+), CD4^(+), CD8^(+), CD4^(+)/CD8^(+)), the KPS score, and the incidence of adverse reactions were compared between the two groups. Results: After the treatment, the objective remission rate of the observation group was 78.38%(29/37), which was higher than 54.05%(20/37) of the control group, and the difference was statistically significant(P<0.05). The TCM syndrome score of the observation group was lower than that of the control group, and the difference was statistically significant(P<0.05). The levels of CD3^(+), CD4^(+), CD4^(+)/CD8^(+) and the KPS score in the observation group were higher than those in the control group, the level of CD8^(+) was lower than that in the control group, and the differences were statistically significant(P<0.05). However, there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05). Conclusions: Yiqi Huatan decoction combined with chemotherapy in the treatment of the elderly patients with advanced NSCLC with qi and yin deficiency syndrome can improve the objective remission rate, the T cell subset levels and the KPS score, and reduce the TCM syndrome score. Moreover, it is superior to single GP chemotherapy treatment.
作者
纪思宇
JI Siyu(Department of Pharmacy of the Second People’s Hospital of Liaoyang,Liaoyang 111000 Liaoning,China)
出处
《中国民康医学》
2023年第2期109-112,共4页
Medical Journal of Chinese People’s Health
关键词
老年
晚期
非小细胞肺癌
化疗
益气化痰方
中医证候积分
T细胞亚群
Elderly
Advanced stage
Non-small cell lung cancer
Chemotherapy
Yiqi Huatan decoction
TCM syndrome score
T cell subset
